TEVA Stock Intrinsic Value – TEVA PHARMACEUTICAL INDUSTRIES Reports Financial Results for Q2 FY2023
August 7, 2023
🌥️Earnings Overview
TEVA PHARMACEUTICAL INDUSTRIES ($NYSE:TEVA) released their financial results for the second quarter of FY2023, ending on August 2 2023, on June 30 2023. Year over year, their total revenue increased by 2.4%, reaching USD 3878.0 million.
Price History
The stock opened at $8.8 and climbed to close at $9.2, marking an impressive 11.6% increase from the previous closing price of $8.3. This increase was attributed to the company’s initiatives to reduce costs and streamline operations. The company’s strong financial performance is further bolstered by its robust pipeline of new products, with six new products expected to launch in the near future. With the strong financial results and promising pipeline, Teva Pharmaceutical Industries is set to continue its positive trajectory in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for TEVA. More…
| Total Revenues | Net Income | Net Margin |
| 15.02k | -2.23k | -0.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TEVA. More…
| Operations | Investing | Financing |
| 1.7k | 798 | -1.91k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TEVA. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 43.09k | 35.39k | 6.29 |
Key Ratios Snapshot
Some of the financial key ratios for TEVA are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -3.6% | -5.4% | -7.4% |
| FCF Margin | ROE | ROA |
| 7.8% | -9.4% | -1.6% |
Analysis – TEVA Stock Intrinsic Value
At GoodWhale, we are currently conducting an analysis of the wellbeing of TEVA PHARMACEUTICAL INDUSTRIES. Using our proprietary Valuation Line we have calculated the fair value of TEVA PHARMACEUTICAL INDUSTRIES share to be around $7.2. At this time, the stock is currently being traded at $9.2, which is overvalued by 28.6%. This discrepancy can be explained by a number of factors, such as market sentiment or speculation, and should be taken into account when considering an investment decision. More…
Summary
Teva Pharmaceutical Industries reported their financial results for the second quarter of FY2023 on June 30 2023, with total revenue of USD 3878.0 million, a 2.4% increase year over year. The stock price reacted positively to the results, moving up the same day. Despite a net loss, investors are encouraged by the revenue growth and should consider investing in Teva Pharmaceutical Industries. With their strong portfolio of products and the potential for future growth, Teva Pharmaceutical Industries could be a good long-term investment.
Related Posts
Recent Posts
